Nilotinib Zentiva (Nilotinib)

Nilotinib selectively blocks the BCR‑ABL, c‑KIT and PDGFR tyrosine kinases by binding to their ATP‑binding sites. This inhibition stops downstream signaling that drives malignant cell growth, leading to reduced proliferation and increased programmed cell death of leukemic cells.

The specific dose and dosing schedule of Nilotinib Zentiva are determined by the prescribing physician based on the patient’s disease stage, prior therapy, and individual health factors. Patients should follow the exact regimen provided by their healthcare professional.

Nilotinib is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should not be used during pregnancy unless the potential benefit justifies the risk. Breastfeeding is not recommended while on treatment, as the drug can be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nilotinib is a second‑generation BCR‑ABL inhibitor that offers higher potency and selectivity compared with first‑generation agents such as imatinib. It is often chosen for patients who have resistance or intolerance to earlier drugs, though safety profiles and drug‑interaction potentials differ and should be evaluated individually.

Nilotinib Zentiva tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Do not store in areas with high humidity or extreme heat.

The medication is taken orally, usually with a low‑fat meal to improve absorption. Patients should swallow the tablet whole with water and follow the timing and dietary instructions given by their prescriber.

The most serious adverse events include QT interval prolongation, which can lead to life‑threatening arrhythmias, severe liver toxicity, and pancreatitis. Regular cardiac monitoring, liver function tests, and pancreatic enzyme assessments are essential to detect these risks early.

Patients with a known hypersensitivity to nilotinib or any of its excipients should avoid the drug. It is also contraindicated in individuals with a history of significant QT prolongation, uncontrolled cardiac disease, or severe hepatic impairment unless specifically advised by a specialist.